Atlas Trials

Robert Redner, MD

2 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Robert Redner, MD

RecordFirmDate
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (NCT03839446)Robert Redner, MD2019-02-28

Track Robert Redner, MD automatically

Every clearance here is in the API, with alerts when new ones post.